메뉴 건너뛰기




Volumn 18, Issue 6, 2006, Pages 693-694

Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin

Author keywords

Central hypothyroidism; Chronic hepatitis C; Hypophysitis; Pegylated interferon alpha; Ribavirin

Indexed keywords

CORTICOTROPIN; GADOLINIUM; PEGINTERFERON ALPHA2A; RIBAVIRIN; THYROTROPIN; THYROXINE;

EID: 33744477063     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200606000-00019     Document Type: Article
Times cited : (31)

References (9)
  • 1
    • 20844458424 scopus 로고    scopus 로고
    • Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C
    • Moncoucy X, Leymarie F, Delemer B, Levy S, Bernard-Chabert B, Bouche O, et al. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005; 29:339-345.
    • (2005) Gastroenterol Clin Biol , vol.29 , pp. 339-345
    • Moncoucy, X.1    Leymarie, F.2    Delemer, B.3    Levy, S.4    Bernard-Chabert, B.5    Bouche, O.6
  • 2
    • 8844247779 scopus 로고    scopus 로고
    • Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: A prospective cohort study
    • Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 2004; 164:2371-2376.
    • (2004) Arch Intern Med , vol.164 , pp. 2371-2376
    • Bini, E.J.1    Mehandru, S.2
  • 3
    • 0036091858 scopus 로고    scopus 로고
    • Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: No association with either interferon dosage or efficacy of therapy
    • Dalgard O, Bjoro K, Hellum K, Myrvang B, Bjoro T, Haug E, Bell H. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251:400-406.
    • (2002) J Intern Med , vol.251 , pp. 400-406
    • Dalgard, O.1    Bjoro, K.2    Hellum, K.3    Myrvang, B.4    Bjoro, T.5    Haug, E.6    Bell, H.7
  • 4
    • 17044415372 scopus 로고    scopus 로고
    • Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C
    • Doi F, Kakizaki S, Takagi H, Murakami M, Sohara N, Otsuka T, et al. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 2005; 25:242-246.
    • (2005) Liver Int , vol.25 , pp. 242-246
    • Doi, F.1    Kakizaki, S.2    Takagi, H.3    Murakami, M.4    Sohara, N.5    Otsuka, T.6
  • 6
    • 1842762908 scopus 로고    scopus 로고
    • Panhypopituitarism in association with interferon-alpha treatment
    • Chan WB, Cockram CS. Panhypopituitarism in association with interferon-alpha treatment. Singapore Med J 2004; 45:93-94.
    • (2004) Singapore Med J , vol.45 , pp. 93-94
    • Chan, W.B.1    Cockram, C.S.2
  • 7
    • 0038100202 scopus 로고    scopus 로고
    • Classification of thyroid diseases: Suggestions for a revision
    • Monaco F. Classification of thyroid diseases: suggestions for a revision. J Clin Endocrinol Metab 2003; 88:1428-1432.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 1428-1432
    • Monaco, F.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.